Strategies to improve treatment outcome in gastric cancer: A retrospective analysis of patients from two high-volume hospitals in Korea and China. by 源��삎�씪 et al.
Oncotarget44660www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 28
Strategies to improve treatment outcome in gastric cancer: 
A retrospective analysis of patients from two high-volume 
hospitals in Korea and China
Kun Yang1,2,3,4,*, Yoon Young Choi3,*, Wei-Han Zhang1,2, Xin-Zu Chen1,2, Mi Kyung 
Song5, Jinae Lee5, Bo Zhang1, Zhi-Xin Chen1, Hyoung-Il Kim3,4, Jia-Ping Chen1, Jae-Ho 
Cheong3, Zong-Guang Zhou1, Woo Jin Hyung3,4, Jian-Kun Hu1,2, Sung Hoon Noh3
1Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China
2Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3Department of Surgery, Severance Hospital, Yonsei University Health System, Yonsei University College of Medicine, Seoul, 
Republic of Korea
4Robot and Minimal Invasive Surgery Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
5Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea
*Co-first authors
Correspondence to: Sung Hoon Noh, email: sunghoonn@yuhs.ac 
Jian-Kun Hu, email: hujkwch@126.com
Keywords: gastric cancer, gastrectomy, tumour characteristics, D2 lymphadenectomy, chemotherapy
Received: December 03, 2015    Accepted: April 23, 2016    Published: May 15, 2016
AbstrAct
China has high incidence of gastric cancer (GC). However, the treatment outcomes 
of China were unsatisfactory compared to those of Korea. We performed this study to 
compare tumour characteristics, treatment parameters, and survival outcomes of GC 
patients between Korea and China based on the databases of two high-volume hospitals, 
with the aim of identifying indicators of GC prognosis. Data of patients undergoing 
gastrectomy for GC from 2006 to 2010 were analysed retrospectively. Subgroup 
survival analyses, stratified by clinicopathologic factors and multivariable analyses, 
were performed. The interactive roles of chemotherapy and D2 lymphadenectomy 
for overall survival were also investigated. Among 1365 Chinese and 4981 Korean 
patients, the proportion of early cancer detection in Chinese patients was much lower 
relative to that of Korean patients. There were no significant differences between 
countries in terms of surgical morbidity and mortality. The overall 5-year survival 
rates were 54.3% and 81.4%; when stratified by clinicopathologic factors, the survival 
were generally statistically higher in Korean patients. Gender, age, T stage, N stage, 
extent of lymphadenectomy, radicality of surgery, resection type, and chemotherapy 
were independently associated with survival in patients without metastasis. Survival 
rates for stage II and III GC differed significantly between the two countries, but 
this difference was eliminated among patients who underwent D2 lymphadenectomy 
or received chemotherapy. These treatments were given to patients with advanced-
stage diagnoses (approximately 20% and 80% of patients, respectively). Treatment 
type was selected as independent prognostic factors in stage I–III and D2/D2+, 
with chemotherapy resulting in the best prognosis. Many differences in GC tumour 
characteristics exist between two countries. Early cancer detection and standardized 
treatment in Korea contribute to superior survival rates. Promotion of an early 
screening program, training and dissemination of standard D2 lymphadenectomy, and 
appropriate applications of chemotherapy would improve survival outcomes.
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IntroductIon
The overall incidence of gastric cancer (GC) has 
been decreasing globally in recent years; however, it 
remains a disease with high incidence and mortality in 
East Asian countries [1]. China has a particularly high 
incidence of GC, accounting for nearly 45% of new GC 
cases and 40% of GC-related deaths worldwide [1, 2]. 
Compared with Korea, the long-term survival rates of GC 
patients, especially when diagnosed in advanced stages, 
are still not satisfactory in China, although they have 
improved in recent years. Despite the fact that GC is the 
most common cancer in Korea, its 5-year overall survival 
rates have been approximately 70% in recent years [3]. 
The reasons accounting for the survival differences 
between these two countries remain unclear and should 
be explored further. Furthermore, unsatisfactory treatment 
outcomes urge us to find effective strategies for treating 
GC in China. Considering the huge number of Chinese 
GC cases, improving treatment would significantly impact 
patients’ survival.
The survival rates after curative gastrectomy for GC 
is higher in East Asian countries than in Western countries 
[4–7]. Therefore, some studies have promoted the 
treatment of GC by comparing East Asian with Western 
countries. Because differences exist in intrinsic biological 
factors, diagnosis, and treatment of GC between Eastern 
and Western countries [4, 8, 9], some findings from 
Western countries have limitations when applied to China. 
However, Korean populations have similarities to Chinese 
populations in environment, genetic susceptibility to GC, 
and application of surgical procedures. Consequently, 
comparing Korea and China may be more meaningful than 
comparing Western and East Asian countries.
Therefore, we compared tumour characteristics, 
treatment parameters, and survival outcomes of GC 
patients between Korea and China based on the databases 
of two high-volume hospitals, with the aim of identifying 
factors that improve GC prognosis. To our knowledge, this 
is the first study to directly compare the characteristics and 
treatment outcomes of GC between Korea and China.
rEsuLts
clinicopathologic characteristics of patients
Clinicopathologic characteristics of patients 
are summarised in Table 1. The proportion of female 
patients in Korea was slightly higher than in Chinese 
patients. The percentage of patients with comorbidities 
was higher in Chinese patients. The locations of tumours 
were statistically different between these two countries. 
In Chinese patients, differentiation was poorer, tumours 
larger, depth of invasion greater, rate of lymph node 
involvement higher, and advanced stages more frequent 
relative to Korean patients. Distant metastasis was also 
more frequent in Chinese patients. The percentage of 
early GC (pT1, EGC) in Korean patients was much higher 
than that of Chinese patients. More Korean than Chinese 
patients were node-negative.
treatment outcomes
Treatment outcomes are summarised in Table 2. 
A higher percentage of minimally invasive surgery, 
including laparoscopic surgery and robotic surgery, was 
conducted in Korea than China. Resection type differed 
significantly between countries, with distal gastrectomies 
performed more frequently in Korean patients and 
non-curative resections performed more frequently in 
Chinese patients. Lymphadenectomy approach also 
differed significantly between the countries. D1/D1+ 
lymphadenectomy was performed more often in Chinese 
than Korean patients; the reverse was true of D2/D2+ 
lymphadenectomy. The mean number of harvested lymph 
nodes was significantly lower in Chinese patients, not only 
overall, but also among patients who received a D2/D2+ 
lymphadenectomy. However, the overall postoperative 
morbidity rates and mortality were not significantly 
different between these two countries. Neo-adjuvant 
chemotherapy was rarely performed in both countries. 
Adjuvant treatment differed significantly between Chinese 
and Korean patients. 
Prognosis of Gc
The 5-year OS for Chinese and Korean patients was 
54.3% and 81.4%, respectively (P < 0.001, Figure 1A). 
When stratified by clinicopathologic characteristics and 
treatment parameters, the prognoses of Korean patients 
were substantially better than those of Chinese patients in 
most subgroup analyses; in advanced GC subgroups, such 
as those receiving R1/R2 resection, whole stomach lesion, 
T4b, N3b, or with distant metastasis, the OS of Chinese 
patients was not significantly different from that of Korean 
patients (Table 3). Prognosis was also compared between 
countries according to stage, and OS was significantly 
lower among Chinese stage II and III patients (Table 3 and 
Figure 1B–1E). 
Independent prognostic factors
Because the prognoses differed in Chinese and 
Korean patients, even for patients in the same TNM 
stages (especially for stage II and III), further analyses 
focused on identifying independent prognostic factors in 
overall. The analysis classified patients into two groups: 
those without distant metastasis (M0) and those with 
metastasis (M1). In M0 patients, gender, age, depth of 
infiltration, nodal status, extent of lymphadenectomy, 
radicality of surgery, resection type, and chemotherapy 
were independently associated with prognosis (Table 4). 
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In M1 patients, tumour size and chemotherapy were 
independent prognostic factors. Among these independent 
prognostic factors, lymphadenectomy and chemotherapy 
were the only clinically-correctable factors; thus, we 
extended our analysis to compare prognoses in patients who 
underwent D2/D2+ lymphadenectomy (Figure 2A–2D) 
or received adjuvant chemotherapy (Figure 3A–3C). 
Intriguingly, the prognostic differences between Chinese 
and Korean patients were attenuated when D2/D2+ 
lymphadenectomy and chemotherapy were analysed 
table 1: General clinicopathological characteristics of the patients between different countries
china
(N = 1365)* 
Korea
(N = 4981)* P value
Gender 0.001
 Female 409 (30.0) 1737 (34.9)
 Male 956 (70.0) 3244 (65.1)
Age (yrs) 0.118
 < 60 768 (56.3) 2684 (53.9)
 ≥ 60 597 (43.7) 2297 (46.1)
comorbidity 738 (54.1) 2427 (48.7) < 0.001
tumor location < 0.001
 Upper third 349 (25.6) 681 (13.7)
 Middle third 180 (13.2) 1365 (27.4)
 Lower third 806 (59.1) 2919 (58.6)
 Whole stomach 30 (2.2) 16 (0.3)
differentiation < 0.001
 G1 15 (1.1) 652 (13.1)
 G2 180 (13.2) 1415 (28.4)
 G3 1170 (85.7) 2914 (58.5)
tumor size (cm) < 0.001
 ≤ 2 200 (14.7) 1665 (33.4)
 ~5.0 645 (47.3) 2277 (45.7)
 ~8.0 399 (29.2) 756 (15.2)
 > 8.0 121 (8.9) 283 (5.7)
Depth of infiltration (pT) < 0.001
 pT1 231 (16.9) 2713 (54.5)
 pT2 172 (12.6) 555 (11.1)
 pT3 85 (6.2) 649 (13.0)
 pT4a 716 (52.5) 1031 (20.7)
 pT4b 161 (11.8) 33 (0.7)
nodal status (pn) < 0.001
 pN0 412 (30.2) 3124 (62.7)
 pN1 245 (18.0) 605 (12.2)
 pN2 222 (16.3) 514 (10.3)
 pN3a 302 (22.1) 457 (9.2)
 pN3b 184 (13.5) 281 (5.6)
distal metastasis (M) < 0.001
 M0 1221 (89.5) 4837 (97.1)
 M1 144 (10.6) 144 (2.9)
stage < 0.001
 I 281 (20.6) 2931 (58.8)
 II 264 (19.3) 797 (16.0)
 III 676 (49.5) 1109 (22.3)
 IV 144 (10.6) 144 (2.9)
*Frequency (percentage).
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table 2: details of treatment and surgical short-term outcomes between different countries
china
(N = 1365)† 
Korea
(N = 4981)† P value
surgical methods < 0.001
 Open surgery 1176 (86.2) 3773 (75.8)
 Laparoscopic surgery 189 (13.9) 779 (15.6)
 Robotic surgery 0 (0) 429 (8.6)
resection type < 0.001
 Distal gastrectomy 793 (58.1) 3660 (73.5)
 Proximal gastrectomy 230 (16.9) 0 (0)
 Total gastrectomy 342 (25.1) 1321 (26.5)
Lymphadenectomy 0.004
 D1/ D1+ 689 (50.5) 2294 (46.1)
 D2/ D2+* 676 (49.5) 2687 (53.9)
radicality of surgery < 0.001
 R0  1239 (90.8) 4780 (96.0)
 R1/R2 126 (9.2) 201 (4.0)
reconstructions 0.000
 Billroth-1 192 (14.07%) 1853 (37.20%)
 Billroth-2 589 (43.15%) 1792 (35.98%)
 Roux-en-Y 354 (25.93%) 1336 (26.82%)
 Esophagogastric anastomosis 230 (16.85%) 0 (0%)
no. of total harvested lymph nodes 27.22 ± 13.01 40.12 ± 16.03 < 0.001
no. of total harvested lymph nodes in d2 subgroup 30.00 ± 12.90 43.42 ± 16.43 < 0.001
no. of lymph nodes with positive metastasis 6.43 ± 8.39 3.07 ± 7.42 < 0.001
Postoperative hospital stays (day) 11.41 ± 7.75 9. 79 ± 9.36 0.000
Estimated blood loss (mL) (4909 patients for analysis) 172.00 ± 154.71 120.27 ± 192.66 0.000
operation time (min) (5806 patients for analysis) 242.34 ± 54.38 169.16 ± 57.49 0.000
number of patients with postoperative morbidity 200 (14.7) 708 (14.2) 0.682
Clavien-Dindo classification of postoperative morbidity 0.166
 I 62 (4.5) 222 (4.5)
 II 75 (5.5) 240 (4.8)
 IIIa 42 (3.1) 156 (3.1)
 IIIb 10 (0.7) 70 (1.4)
 IVa 3 (0.2) 3 (0.1)
 IVb 2 (0.1) 5 (0.1)
 V 6 (0.4) 12 (0.2)
Mortality 6 (0.4) 12 (0.2) 0.221
chemotherapy < 0.001
 No chemotherapy 764 (56.0) 3411 (68.5)
 Neo-adjuvant chemotherapy 12 (0.9) 87 (1.7)
 Adjuvant chemotherapy 575 (42.1) 1408 (28.3)
 Unclear 14 (1.0) 75 (1.5)
*: D2 included No.14v lymph nodes dissection.
†Frequency (percentage).
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in isolation. Furthermore, country was not selected by 
multivariable analyses as an independent prognostic factor 
in either the M0 or M1 group (Table 4).
Effects of lymphadenectomy and chemotherapy 
by Gc stage
To scrutinize the effects of lymphadenectomy and 
chemotherapy across all stages, 5-year OS was compared 
at each stage (Table 5). The benefit of chemotherapy was 
observed mainly in stage III and IV, and the prognosis 
of the chemotherapy group was significantly better than 
the no-chemotherapy group in stage II when D1/D1+ 
lymphadenectomy was  performed. When the benefit of 
D2/D2+ vs. D1/D1+ lymphadenectomy was compared, 
the prognosis of the D2/D2+ group was better in stage 
III, but not stages I, II, or IV. Intriguingly, D2/D2+ 
lymphadenectomy was positively related to prognosis in 
stage II when the patients did not receive chemotherapy. 
different treatment in different countries and 
the possible benefit of D2/D2+ lymphadenectomy 
and chemotherapy in china 
We assessed the proportions of patients received D2/
D2+ lymphadenectomy and/or chemotherapy, stratifying 
these independent and clinically-correctable prognostic 
factors by stage in both countries (Table 6). Approximately 
50% of Chinese patients with advanced disease (stage III 
and IV) received D2/D2+ lymphadenectomy or 
chemotherapy, while over 80% of patients in Korea. Only 
around 20% of Chinese patients were treated by both 
D2/D2+ lymphadenectomy and chemotherapy; but over 
60% of patients in Korea. When comparing the benefit 
of the combination of D2/D2+ lymphadenectomy and 
chemotherapy according to each stage in Chinese patients, 
D1/D1+ lymphadenectomy without chemotherapy in stage 
II and III had the poorest prognosis, whereas the benefit 
from D2/D2+ lymphadenectomy with chemotherapy was 
prominent in stage III (Figure 4A–4D). In multivariable 
analyses, treatment type was selected as an independent 
prognostic factor in M0 patients, where D2/D2+ 
lymphadenectomy with chemotherapy showed the 
best prognosis (Table 7). Treatment type was also an 
independent prognostic factor in M1 patients. However, 
only chemotherapy was positively correlated to better 
prognosis; D2/D2+ lymphadenectomy was not. 
dIscussIon
In our analyses, the 5-year OS rate of Korean GC 
patients was substantially higher than that of Chinese 
Figure 1: Kaplan-Meier survival analysis of patients between china and Korea. (A) Overall patients. (b–E) Patients stratified 
by stage. (B) Stage I patients; (C) Stage II patients; (D) Stage III patients; (E) Stage IV patients.
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Table 3: Survival analyses stratified by clinicopathologic characteristics and treatment parameters 
in different countries
china (N = 1105) Korea (N = 4877)
P value†
N 5-y osr (%) N 5-y osr (%)
Gender
 Female 324 56.3 1700 83.3 < 0.001
 Male 781 53.4 3177 80.4 < 0.001
Age (yrs)
 < 60 618 55.4 2643 84.5 < 0.001
 ≥ 60 487 52.9 2234 77.6 < 0.001
Longitudinal tumor location
 Upper third 280 43.7 670 76.9 < 0.001
 Middle third 140 54.4 1334 82.4 < 0.001
 Lower third 661 59.9 2861 82.1 < 0.001
 Whole stomach 24 23.4 12 43.7 0.155
differentiation
 G1 11 90.0 645 92.0 0.814
 G2 148 62.7 1387 81.0 < 0.001
 G3 946 52.6 2845 79.1 < 0.001
tumor size (cm)
≤ 2 157 83.8 1660 94.7 < 0.001
~ 5.0 523 59.2 2232 83.0 < 0.001
~ 8.0 327 40.0 719 62.6 < 0.001
> 8.0 98 28.1 266 40.3 0.026
Depth of infiltration (pT)
 pT1 180 91.4 2710 95.0 0.056
 pT2 150 71.4 547 85.0 0.001
 pT3 73 54.3 621 75.3 < 0.001
 pT4a 573 44.4 970 47.7 0.352
 pT4b 129 26.1 29 23.6 0.278
nodal status (pn)   
 pN0 320 80.9 3111 92.8 < 0.001
 pN1 200 61.8 583 84.1 < 0.001
 pN2 184 60.1 493 68.9 0.020
 pN3a 245 32.8 432 45.1 0.001
 pN3b 156 16.8 258 22.9 0.249
distal metastasis (M)
 M0 981 59.2 4748 83.0 < 0.001
 M1 124 15.0 129 21.6 0.404
stage
 I 221 91.6 2928 94.9 0.106
 II 216 67.9 772 81.2 0.001
 III 544 42.7 1048 51.6 0.001
 IV 124 15.0 129 21.6 0.404
surgical methods
 Open surgery 943 52.9 3675 78.1 < 0.001
 Minimal invasive surgery 162 62.2 1202 92.0 < 0.001
resection type
 Subtotal gastrectomy 827 59.1 3606 86.1 <0.001
 Total gastrectomy 278 40.0 1271 68.0 <0.001
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Lymphadenectomy
 D1/ D1+ 578 49.4 2278 91.3 < 0.001
 D2/ D2+* 527 59.6 2599 72.3 < 0.001
radicality of surgery
 R0 996 58.6 4695 83.6 < 0.001
 R1/R2 109 14.4 182 25.7 0.065
chemotherapy
 No 593 50.0 3396 91.5 < 0.001
 Yes  512 59.2 1481 57.9 0.347
Abbreviations: OSR, overall survival rate.
*: D2 included No.14v lymph nodes dissection.
† p-value for log-rank test.
table 4: the prognostic factors on the univariable and multivariable cox-proportional hazard 
regression analyses
M0 patients (N = 5729) M1 patients (N = 253)
univariable Hr
(95% cI) P value
Multivariable 
Hr*
(95% cI)
P value univariable Hr(95% cI) P value
Multivariable 
Hr*
(95% cI)
P value
country < 0.001 0.409
 China 1 1
 Korea 0.37 [0.33–0.42] 0.89 [0.68–1.17]
Gender < 0.001 0.011 0.125
 Male 1 1 1
 Female 0.75 [0.66–0.85] 0.85 [0.74–0.96] 1.25 [0.94–1.66]
Age (yrs) < 0.001 < 0.001 0.118
 < 60 1 1 1
 ≥ 60 1.48 [1.32–1.66] 1.50 [1.33–1.68] 0.80 [0.60–1.06]
tumor location < 0.001 0.676
 Upper third 1 1
 Middle third 0.57 [0.48–0.68] < 0.001 0.95 [0.64–1.42] 0.794
 Lower third 0.66 [0.57–0.76] < 0.001 0.83 [0.59–1.18] 0.309
 Whole stomach 3.29 [1.92–5.63] < 0.001 1.07 [0.57–2.02] 0.839
differentiation < 0.001 0.069
 G1 1 1
 G2 2.78 [2.04–3.79] < 0.001 3.58 [0.48–26.58] 0.212
 G3 3.66 [2.73–4.91] < 0.001 5.20 [0.73–37.16] 0.101
tumor size (cm) < 0.001 < 0.001 < 0.001
 ≤ 2 1 1 1
 ~5.0 3.30 [2.69–4.06] < 0.001 1.08 [0.43–2.72] 0.869 1.12 [0.45–2.82] 0.810
 ~8.0 7.70 [6.23–9.52] < 0.001 1.93 [0.78–4.77] 0.152 1.90 [0.77–4.70] 0.163
 > 8.0 12.28 [9.65–15.63] < 0.001 2.65 [1.06–6.62] 0.036 2.64 [1.06–6.58] 0.038
Depth of infiltration (pT) < 0.001 < 0.001 0.188
 pT1 1 1 1
 pT2 3.56 [2.80–4.52] < 0.001 2.89 [2.23–3.74] < 0.001 8.37 [0.87–80.81] 0.066
 pT3 5.51 [4.42–6.87] < 0.001 3.60 [2.78–4.67] < 0.001 3.08 [0.40–23.70] 0.280
 pT4a 12.04 [10.07–14.38] < 0.001 6.07 [4.80–7.66] < 0.001 5.08 [0.71–36.36] 0.106
 pT4b 23.61 [17.83–31.27] < 0.001 7.31 [5.29–10.10] < 0.001 4.74 [0.65–34.44] 0.124
nodal status (pn) < 0.001 < 0.001 0.063
 pN0 1 1 1
 pN1 2.65 [2.17–3.24] < 0.001 1.49 [1.20–1.85] < 0.001 1.12 [0.53–2.36] 0.759
 pN2 4.62 [3.86–5.54] < 0.001 2.10 [1.70–2.59] < 0.001 0.98 [0.46–2.09] 0.958
 pN3a 9.94 [8.46–11.68] < 0.001 3.90 [3.18–4.77] < 0.001 1.24 [0.65–2.37] 0.506
 pN3b 17.34 [14.49–20.75] < 0.001 6.32 [5.05–7.90] < 0.001 1.71 [0.92–3.19] 0.093
Oncotarget44667www.impactjournals.com/oncotarget
patients. We performed multivariable analyses to 
identify the prognostic factors that most influenced 
survival. After adjustment, country was not a significant 
independent prognostic factor. Of the factors identified 
as independent prognostic factors, some are beyond 
medical control (including gender, age, depth of 
infiltration, lymph node metastasis, and resection type), 
whereas other factors are capable of influence by doctors 
(including lymphadenectomy, radicality of surgery, and 
chemotherapy). To our knowledge, this is the first study, 
not only emphasizing the different cancer characteristics 
between the two countries, but also focusing on the roles 
of doctor-correctable factors. This is also the first study to 
directly propose the solutions to improve the treatment of 
GC in China.
The proportion of early cancers was much 
lower and the advanced stages were more frequent in 
Chinese patients. Conversely, nearly 60% of Korean 
patients were diagnosed within early stages of GC. 
Therefore, it is intuitive that the higher proportion 
of advanced-stage patients contributed to the 
poorer survival of Chinese patients. Thanks to the 
national, population-based GC screening program 
established in Korea in 1999 [10], the percentage of 
Lymphadenectomy < 0.001 0.015 0.288
 D1/D1+ 1 1 1
 D2/D2+ 1.91 [1.70–2.15] 0.85 [0.74–0.97] 1.17 [0.88–1.56]
radicality of surgery < 0.001 < 0.001 0.578
 R0  1 1 1
 R1/R2  5.00 [3.84–6.50] 1.84 [1.40–2.41] 1.10 [0.78–1.56]
resection type < 0.001 0.011 0.004
 Subtotal  1 1 1
 Total  2.03 [1.81–2.29] 1.17 [1.04–1.32] 1.50 [1.14–1.98]
chemotherapy < 0.001 0.001 0.002 0.008
 No  1 1 1 1
 Yes 3.11 [2.78–3.49] 0.79 [0.69–0.91] 0.62 [0.46–0.84] 0.66 [0.49–0.90]
Abbreviations: HR, hazard ratio.
*forward selection with likelihood ratio.
Figure 2: Kaplan-Meier survival analysis of patients with D2 or D2+ lymphadenectomy stratified by stage between 
china and Korea. (A) Stage I patients; (b) Stage II patients; (c) Stage III patients; (d) Stage IV patients.
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GC diagnosed in early stage has gradually increased 
from 15% during 1974–1992 to 58% in 2009 [11]. 
In recent years, despite a slight upward trend of early 
GC detection in China due to the availability of upper 
gastrointestinal endoscopy and a shift towards health- 
consciousness in China [7, 12, 13], the proportion of 
early GC diagnoses is still low, and advanced GC remains 
the leading health burden and cause of cancer-related 
mortality. Fortunately, annual reports indicate that the 
incidence and mortality of GC has decreased and the 
mortality-to-prevalence ratio of GC has tended to decline 
in recent years [11]. These trends have resulted from 
the China Cancer Prevention and Control Program, a 
governmental platform dedicated to prevention, screening, 
and surveillance for cancers (including GC), although 
there is not a formal, specialized, nationwide cancer-
screening program [11]. Establishment of a formal and 
specialized nationwide screening program for GC will 
further promote early detection, which will also mitigate 
the extent of medically-uncontrollable factors that impact 
survival. In addition, early detection and intervention of the 
precancerous lesions and eradication of the Helicobacter 
pylori infection would also contributable [14].
Controversy over lymphadenectomy in GC 
surgery has persisted for several decades. Several large 
randomized studies and meta-analyses found that the D2 
procedure was significantly associated with postoperative 
morbidity and mortality, rather than conferring a survival 
benefit [15–17]. Therefore, limited lymphadenectomy 
was utilized in a study of GC patients in Western 
countries [18]. However, not only the prognosis of 
surgery-only group but also surgery with chemotherapy 
group from Western trials was significantly poorer 
compared with that of surgery-only group from Eastern 
trials where more extensive lymphadenectomy (D2) 
has been a standard; those difference partly caused by 
the insufficient lymphadenectomy in Western trials 
[19–21]. Furthermore, the 15-year follow-up results of 
a Dutch trial indicate that D2 lymphadenectomy could 
decrease locoregional recurrence and GC-related death 
relative to D1 lymphadenectomy [22]. In our study, D2 
lymphadenectomy was a positive prognostic factor in stage 
II and III patients, and D2 lymphadenectomy alone even 
cured some stage II patients. However, less than 50% of 
Chinese patients with stage II and III GC have undergone 
D2 lymphadenectomy, whereas more than 80% of Korean 
patients with the same stage underwent this surgery. This 
pattern explains why the survival of patients with stage 
II and III GC was significantly different between these 
two countries in initial analyses but was similar when the 
analyses were confined to the patients who underwent D2/
D2+ lymphadenectomy. 
Figure 3: Kaplan-Meier survival analysis of patients with chemotherapy stratified by stage between China and Korea. 
(A) Stage II patients; (b) Stage III patients; (c) Stage IV patients.
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In the past two decades, the Chinese anti-cancer 
association/Gastric Cancer Association have promoted a 
program of itinerant lectures on standard GC operation. 
Due to efforts to spread training for D2 lymphadenectomy 
in China, GC surgery has become more standardized in 
recent years. Our published data demonstrate that the 
proportion of D2/D2+ lymphadenectomy from 2000 to 
2005 was approximately 10% but increased to nearly 
40% after 2006, an expansion that was accompanied 
by an increase in the number of harvested lymph nodes 
and improved OS [7], demonstrating the survival benefit 
brought by D2 lymphadenectomy. 
For safety reasons, Western guidelines recommend 
the performance of D2 surgery only in high-volume centres 
by experienced surgeons [23, 24]. Because the present 
results were from two large volume hospitals in two 
countries, there was no significant differences in morbidity 
and mortality even after D2 lymphadenectomy. However, 
it has been widely reported that D2 lymphadenectomy can 
be routinely performed with low morbidity and mortality 
Table 5: Survival of patients stratified by stages according to lymphadenectomy and chemotherapy 
in overall population (N = 5982)
ngroup 1
5–y 
osgroup 1
ngroup 2
5–y 
osgroup 2
P value† unadjusted Hr (95% cI) P value
Adjusted Hr 
(95% cI)* P value
Adjusted Hr 
(95% cI)* for 
patients with r0 
resection
P value
Without chemotherapy (Group 1) Vs with chemotherapy (Group 2)
I 3065 94.7% 84 90.4% 0.162 1.60 [0.82–3.11] 0.165 1.22 [0.54–2.71] 0.635 1.34 [0.60–2.96] 0.474
II 419 76.4% 569 78.6% 0.404 0.89 [0.68–1.17] 0.405 0.84 [0.62–1.14] 0.255 0.83 [0.61–1.12] 0.226
III 438 40.2% 1154 51.8% < 0.001 0.70 [0.60–0.81] < 0.001 0.69 [0.59–0.81] < 0.001 0.68 [0.57–0.80] < 0.001
IV 67 7.3% 186 22.4% 0.001 0.62 [0.45–0.84] 0.002 0.60 [0.42–0.86] 0.006 0.33 [0.13–0.87] 0.025
Group 1 VS Group 2 in D2/D2+ lymphadenectomy group
I 993 94.3% 38 92.0% 0.983 1.01 [0.31–3.28] 0.983 1.21 [0.29–5.00] 0.794 1.21 [0.29–5.00] 0.794
II 304 80.5% 415 78.5% 0.531 1.12 [0.79–1.57] 0.532 1.05 [0.71–1.55] 0.814 1.06 [0.72–1.56] 0.785
III 266 46.4% 947 53.9% 0.007 0.78 [0.64–0.94] 0.008 0.70 [0.57–0.86] 0.001 0.69 [0.56–0.85] < 0.001
IV 33 3.0% 130 21.5% 0.003 0.55 [0.37–0.83] 0.004 0.53 [0.31–0.91] 0.021 –# –#
Group 1 VS Group 2 in D1/D1+ lymphadenectomy group
I 2072 95.0% 46 89.0% 0.060 2.14 [0.95–4.79] 0.065 1.40 [0.51–3.87] 0.515 1.42 [0.52–3.93] 0.497
II 115 65.6% 154 79.0% 0.010 0.53 [0.33–0.87] 0.011 0.51 [0.30–0.89] 0.018 0.51 [0.30–0.89] 0.018
III 172 30.6% 207 42.7% 0.001 0.67 [0.52–0.86] 0.002 0.60 [0.45–0.80] < 0.001 0.60 [0.45–0.82] 0.001
IV 34 11.4% 56 24.0% 0.044 0.62 [0.38–0.99] 0.047 0.43 [0.24–0.78] 0.005 –# –#
D1/D1+ (Group 1) VS D2/D2+ lymphadenectomy (Group 2)
I 2118 94.8% 1031 94.2% 0.323 1.18 [0.85–1.62] 0.324 0.94 [0.66–1.34] 0.720 0.98 [0.68–1.39] 0.888
II 269 73.3% 719 79.1% 0.186 0.80 [0.60–1.08] 0.146 0.78 [0.56–1.10] 0.160 0.76 [0.54–1.07] 0.118
III 379 37.2% 1213 52.2% < 0.001 0.70 [0.60–0.81] < 0.001 0.79 [0.66–0.95] 0.014 0.81 [0.67–0.99] 0.040
IV 90 19.3% 163 17.8% 0.283 1.17 [0.88–1.56] 0.288 1.39 [0.98–1.97] 0.066 2.64 [0.96–7.26] 0.060
Group 1 Vs Group 2 in with chemotherapy group
I 46 89.0% 38 92.0% 0.231 0.44 [0.11–1.74] 0.243 0.16 [0.015–1.68] 0.127 0.16 [0.015–1.68] 0.127
II 154 79.0% 415 78.5% 0.535 1.14 [0.75–1.75] 0.535 1.07 [0.65–1.77] 0.787 1.05 [0.64–1.74] 0.837
III 207 42.7% 947 53.9% 0.022 0.79 [0.64–0.97] 0.023 0.73 [0.57–0.93] 0.011 0.74 [0.57–0.97] 0.025
IV 56 24.0% 130 21.5% 0.291 1.22 [0.84–1.75] 0.296 1.07 [0.68–1.69] 0.763 –# –#
Group 1 Vs Group 2 in without chemotherapy group
I 2072 95.0% 993 94.3% 0.196 1.24 [0.89–1.72] 0.197 0.95 [0.66–1.37] 0.786 0.98 [0.68–1.41] 0.900
II 115 65.6% 304 80.5% 0.004 0.54 [0.35–0.81] 0.003 0.56 [0.34–0.93] 0.023 0.56 [0.34–0.93] 0.023
III 172 30.6% 266 46.4% 0.002 0.69 [0.54–0.88] 0.002 0.67 [0.48–0.93] 0.016 0.69 [0.50–0.95] 0.025
IV 34 11.4% 33 3.0% 0.068 1.59 [0.96–2.64] 0.074 1.79 [0.96–3.34] 0.069 –# –#
Abbreviations: N, number; OS, overall survival; HR, hazard ratio.
Note: The values of group 1 were regarded as references for the HR analyses.
†p-value for log-rank test.
* Adjust for country, gender, age, surgical methods, tumor location, differentiation, tumor size, T stage, N stage, resection type, 
lymphadenectomy, radicality of surgery, chemotherapy.
#The valid sample size is too small to calculate the adjust HR.
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in small-volume hospitals [17, 25, 26]. Therefore, there 
is no longer a sustainable argument against standard D2 
gastrectomy in modern surgery for invasive GC, especially 
given the poor results of para-aortic lymphadenectomy 
from the JCOG 9501 trial [23, 27, 28]. Nonetheless, the 
training necessary for D2 gastrectomy and the quality of 
performance remain challenges need to be addressed.
Despite the receipt of D2 lymphadenectomy for 
resectable GC, about 40% of patients relapsed within three 
years of surgery [21, 27]. Therefore, various adjuvant 
treatment modalities have been investigated to reduce 
postoperative recurrence, with some Western clinical 
trials yielding favourable results [19, 20]. However, these 
results should be interpreted and applied cautiously to East 
Asian  patients because lymphadenectomy in these studies 
was limited, and the results tended to vary by geographic 
region [29]. Two large randomized controlled trials in Asia 
(ACTS-GC trial and CLASSIC trial) have established the 
benefit role of adjuvant chemotherapy in stage II or III GC 
patients after D2 gastrectomy [21, 30]. 
In accordance with previous studies, our results 
demonstrate that chemotherapy can improve the prognosis 
of patients with stage III GC, even partly compensating for 
the absence of D2 lymphadenectomy in patients with stage 
II GC [19–21, 30]. In addition, adjuvant chemotherapy 
increased the OS of patients with distant metastasis. The 
proportion of stage III or IV patients receiving adjuvant 
therapy—those most likely to benefit from the addition 
Figure 4: Kaplan-Meier survival analysis of chinese patients according to the treatment type in each stage. (A) Stage I 
patients; (b) Stage II patients; (c) Stage III patients; (d) Stage IV patients.
Table 6: Proportion of patients who received different treatment (lymphadenectomy and/or 
chemotherapy) according to each stage in two different countries
china Korea
total 
number of 
patients
number 
of Patients 
with D2/
D2+ (%)
number of 
Patients with 
chemotherapy (%)
number of 
Patients with 
D2/D2+ and 
chemotherapy (%)
total 
number 
of 
patients
number of 
Patients with 
D2/D2+ (%)
number of 
Patients with 
chemotherapy (%)
number of Patients 
with D2/D2+ and 
chemotherapy (%)
stage I 281 149 (53.0) 82 (29.2) 39 (13.9) 2931 917 (31.3) 13 (0.4) 5 (0.2)
stage II 264 130 (49.2) 131 (49.6) 58 (22.0) 797 640 (80.3) 456 (57.2) 367 (46.0)
stage III 676 325 (48.1) 298 (44.1) 141 (20.9) 1109 1021 (92.1) 904 (81.5) 836 (75.4)
stage IV 144 72 (50.0) 76 (52.8) 36 (25.0) 144 109 (75.7) 122 (84.7) 96 (66.7)
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of chemotherapy—was considerably smaller in China 
than in Korea. Several factors may account for this. 
We included patients from 2006 to 2010 in this study, 
but little evidence supporting the application of 
adjuvant therapy after D2 surgery occurred during that 
time. Therefore, some patients with curative surgery 
did not wish to receive chemotherapy because of the 
risk of toxic effects [29]. This is also true for Korean 
patients with stage II GC; low compliance of patients 
from both countries contributes to this phenomenon. 
Future attention should be paid in China to the spread 
of and education about chemotherapy, the invention 
of new drugs or regimens with lower toxicity, and the 
appropriate application of chemotherapy. With respect to 
lymphadenectomy and chemotherapy, factors controllable 
in clinical practice, only 20% of stage II-IV patients were 
given D2 lymphadenectomy and adjuvant chemotherapy 
although they account for nearly 80% of GC cases in 
China. In our study, both D2/D2+ and chemotherapy were 
selected as independent prognostic factors, and the best 
prognosis appeared in the patients treated by D2/D2+ 
with chemotherapy; if the proportion of patients with D2 
lymphadenectomy and adjuvant chemotherapy increases, 
long-term survival will improve.
There are some limitations of this study. Firstly, 
selection bias, detection bias, and performance of analysis 
bias are possible in any retrospective study [31]. Secondly, 
our data are from only two institutions, one Chinese and 
one Korean; therefore, the data may not represent the 
general population well. However, the numbers of GC 
table 7: Multivariable cox-proportional hazard regression analysis in chinese population 
(N = 1105)
M0 patients (N = 981) M1 patients (N = 124)
Multivariable 
Hr* P value
Multivariable 
Hr† P value
treatment < 0.001 treatment 0.001
 D1/D1+ without chemotherapy 1  D1/D1+ without chemotherapy 1
 D1/D1+ with chemotherapy 0.63 [0.49–0.81] < 0.001  D1/D1+ with chemotherapy 0.45 [0.25–0.79] 0.006
 D2/D2+ without chemotherapy 0.86 [0.67–1.11] 0.244  D2/D2+ without chemotherapy 1.53 [0.88–2.63] 0.129
 D2/D2+ with chemotherapy 0.44 [0.32–0.59] < 0.001  D2/D2+ with chemotherapy 0.91 [0.53–1.57] 0.732
radicality of surgery 0.001 tumor size (cm) 0.005
 R0 1  ≤ 2 1
 R1/R2 1.97 [1.30–2.99]  ~5.0 3.43 [0.46–25.78] 0.232
Depth of infiltration (pT) < 0.001  ~8.0 5.81 [0.78–43.40] 0.087
 pT1 1  > 8.0 7.73 [1.02–58.64] 0.048
 pT2 2.28 [1.32–3.95] 0.003
 pT3 3.31 [1.84–5.94] < 0.001
 pT4a 3.80 [2.34–6.18] < 0.001
 pT4b 4.18 [2.39–7.32] < 0.001
nodal status (pn) < 0.001
 pN0 1
 pN1 1.82 [1.28–2.59] 0.001
 pN2 1.80 [1.26–2.57] 0.001
 pN3a 3.92 [2.83–5.43] < 0.001
 pN3b 5.25 [3.64–7.57] < 0.001
Abbreviations: HR, hazard ratio.
* forward selection (likelihood ratio) with treatment type, gender, age, surgical methods, tumor location, differentiation, tumor 
size, T stage, N stage, resection type, radicality of surgery.
† forward selection (likelihood ratio) with treatment type, gender, age, surgical methods, tumor location, differentiation, tumor 
size, T stage, N stage, M stage, resection type, radicality of surgery.
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surgeries performed in these two institutions are large, 
and the patients’ origins cover large areas of China and 
Korea, which may serve as representative for two large 
populations. Thirdly, our study was confined to cases 
with gastrectomy, excluding patients who underwent non-
resectional surgery.
In conclusion, many differences in tumour 
characteristics exist between these two countries. A high 
percentage of patients diagnosed GC in early stages and 
standardized treatment in Korea contributes to better 
survival than China. To improve survival outcomes in 
China, the promotion of an early screening program, 
training and spread of standard D2 lymphadenectomy, and 
appropriate applications of chemotherapy are necessary.
MAtErIALs And MEtHods
Patients
This study consisted of 6346 GC patients, 1365 
Chinese and 4981 Korean, diagnosed between January 
2006 and December 2010. Data were extracted from the 
databases of West China Hospital, Sichuan University, and 
Severance Hospital, Yonsei University Health System, 
and analysed retrospectively (Figure 5). The diagnosis 
of gastric adenocarcinoma for all patients was confirmed 
by upper endoscopy and biopsy. Inclusion criteria were 
the following: all cases of early and advanced GC, 
both curative and palliative gastrectomies, and patients 
with total or subtotal gastrectomies. Non-resectional 
surgeries, however, such as bypass surgery, gastrostomy, 
or jejunostomy, were excluded. Patients with other 
gastric pathologies, such as lymphoma, gastrointestinal 
stromal tumour or adenosquamous carcinoma, previous 
malignancies, remnant GC, or those treated by wedge 
resection or endoscopic resection were also excluded. 
The West China Hospital Research Ethics Committee 
and Institutional Review Board of Severance Hospital, 
Yonsei University Health System, approved retrospective 
analyses of anonymous data (4-2015-0647). Signed patient 
informed consent was waived because of the retrospective 
nature of the analysis.
treatments
All patients underwent gastrectomy with D1, D1+, 
D2, or D2+ lymphadenectomy for GC as defined by the 
Japanese Classification of Gastric Carcinoma [32]. Total 
or subtotal gastrectomy was performed according to the 
location of the primary lesion. Billroth I, Billroth II, or 
Figure 5: Flow chart showing selection procedure of patients.
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Roux-en-Y anastomosis with hand-sewn or mechanical 
staples was performed to reconstruct the digestive tract 
after distal gastrectomy. Esophagogastric anastomosis 
was used after proximal gastrectomy, and Roux-en-Y 
esophagojejunostomy was utilized for total gastrectomy. 
Chemotherapy treatments consisted of fluoropyrimidine 
alone or a fluoropyrimidine/platinum-based regimen.
outcomes measurements
Clinicopathologic features, treatment outcomes, 
morbidity and mortality (according to the Clavien-
Dindo Classification), and overall survival (OS) were 
compared [33]. Patients underwent follow-ups conducted 
by telephone calls, letters, or outpatient visits. Survival 
status at the last follow-up for Korean patients was 
also based on data registered with the Korean National 
Cancer Center. The follow-up information was updated 
in December 2014 for Chinese patients and March 2014 
for Korean patients. The overall follow-up rate was 
95.6% (6069/6346). OS was calculated from the date of 
operation until the date of death or the last follow-up. 
The mean follow-up duration was 69.3 ± 20.3 months in 
Chinese patients and 56.2 ± 16.9 in Korean patients. All 
terminologies were based on the Japanese Classification of 
Gastric Carcinoma [34].
statistical analysis
The assumption of normality for continuous 
variables was assessed by the Kolmogorov-Smirnov 
test. All data are reported as mean ± standard deviation 
for continuous variable or frequency (percentage) for 
categorical variables. An independent two-sample 
t-test, Pearson’s chi-square test (or Fisher’s exact test), 
or Spearman’s test were used to compare differences 
between the two countries, as appropriate. Survival rates 
were calculated by Kaplan-Meier estimator and compared 
by the log-rank test. Univariable or multivariable Cox 
proportional hazards regression models were used 
to identify independent prognostic factors. Variables 
included in multivariable models were selected by 
the forward method with likelihood ratio (two-tailed 
p ≤ 0.05). Two-tailed p-values of less than 0.05 were 
considered statistically significant. Statistical analyses 
were performed by using SPSS 19.0 software (SPSS, 
Chicago, IL, USA).
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